Why Kenvue Trusts Our Microbial Testing for Product Release

The Head of Microbial Quality and Sterility Assurance Shares Why They Rely on Accugenix® and Celsis®

Question: Charles River has purposely built a portfolio to bring progressive products and services that deliver accurate, relevant, sand reliable data to fuel confident decision making for our clients. As Head of Microbial Quality and Sterility Assurance at Kenvue, what sets our microbial solutions apart from the rest?
Dr. Miguel Nogueras: Charles River is a trusted partner across industries, with products developed by microbiology experts dedicated to creating healthier lives. Driven by science and compassion, you treat clients like family. Your contributions advance health sciences, partnering with firms like Kenvue to enhance everyday life. At Kenvue, we value partners who share our commitment to improving lives, and you deliver that through your products and services.

Q: How is Kenvue currently using Accugenix and Celsis? In what ways have they impacted the quality and reliability of your final product release testing?
Dr. Nogueras: At Kenvue, we empower consumers through everyday care. Building trust ensures our products are top of mind when needed, but availability is just as critical. As a senior leader, I ensure our products remain accessible at retailers, much like a point-of-care approach.

Accugenix is a trusted partner, supporting us in microbial recovery challenges. As the industry gold standard for rapid microbiological identification, it enables us to expedite investigations and make informed decisions. Charles River’s quick response, accuracy, and customer-focused model align with our consumer-centric supply chain, ensuring we meet customer needs. Accugenix plays a key role in upholding our Kenvue promise.

Similarly, Charles River helps us meet consumer demands through rapid microbiological testing, accelerating product release. While faster market access is beneficial, Celsis also optimizes inventory management by reducing storage needs and warehousing costs. For Kenvue, it's not just about speed but streamlining the entire supply chain with rapid microbiological technology. Celsis’ global presence ensures standardization across markets, and its engaged staff has facilitated regulatory relationships, simplifying implementation.
[画像:Headshot of Dr. Miguel Nogueras showing a smiling man with a beard]

"What sets Charles River apart is your groundwork in establishing scientifically validated methods, easing the path to acceptance for end-users. Your expertise helps us navigate regulatory and geopolitical challenges, making you a trusted partner."
Dr. Miguel Nogueras, Head of Microbial Quality and Sterility Assurance, Kenvue

Q: When thinking about the ever-changing global regulatory requirements, how can partnering with a CRO like Charles River help clients navigate this evolving landscape?
Dr. Nogueras: This is a crucial question, not just for Kenvue, but for the entire industry. Many companies want to adopt new technologies but hesitate due to regulatory concerns. The common response is, "We support rapid technology but don’t want to be the first." The reluctance often stems from the costs and resources required for regulatory submission.

What sets Charles River apart is your groundwork in establishing scientifically validated methods, easing the path to acceptance for end-users. Your expertise helps us navigate regulatory and geopolitical challenges, making you a trusted partner. To fulfill our promise of delivering everyday care through Kenvue products, we must collaborate with CROs like Charles River to better meet market demands through reliable science while maintaining shareholder value.

Q: The advent of Artificial Intelligence (AI) and Machine Learning (ML) is redefining the relationship between science and technology. In your opinion, what does future innovation look like for innovation in the microbial detection space?
Dr. Nogueras: The advent of Artificial Intelligence (AI) and Machine Learning (ML) is redefining the relationship between science and technology. In your opinion, what does future innovation look like for innovation in the microbial detection space?

Microbiology is a science of probabilities, rarely black and white. This is an opportunity to evolve, adapt, and stay ahead. As operational costs rise and quality demands increase, the industry will shift from finished product testing to process monitoring. AI and ML will drive this transformation, enabling faster, more cost-effective product releases while enhancing safety and efficacy insights.